Sustainability Issues in the Pharmaceutical Sector

As I wrote in my blog post on ”Corporations and a diverse workforce” I and Tove Engström, (director Corporate Brand and Corporate Responsibility, AstraZeneca Sweden) participated in the Pharma Online Event for their Pharma Network on May 22. Tove talked about the need to secure the competence supply to our sector. Less and less students study science and engineering classes, which of course presents a huge risk to us looking into the future. Where will we find skilled employees? AstraZeneca is not the only corporation in Sweden who have decided to start their own educational programs on college and/or university level. Volvo Trucks is another fairly recent example.

My presentation was a more ”traditional sustainability lecture”. I touched upon issues such as

- ethics and especially LIF’s ethical rules

- access to medicines

- addition of ”prevention and creation of health” to our core business of ”treatment and cure”

- animal testing and 3R (replace, refine, reduce)

but focused of course on evironmental sustainability initiatives from industry and on the regulatory developments in the field (of which you can read in my blog post from Nov 29, 2011).

I have just started my lecture...

I have just started my lecture...

If you recieved the Pharma Online Newsletter earlier today you are able to read a summary of my presentation and the discussions. The headline for the summary is ”LIF vill ha gröna incitament i förmånssystemet” (in English roughly: LIF wants green economic incentives within the pricing and re-imbursement system).

And the implementation of green economic incentives was really a key message of my talk. If you have followed my blog over the recent year or so you know that I strongly believe that regulatory initiatives on the EU-level such as implementing environmental requirements into GMP needs to be complemented with market driven incentives in the Swedish pricing and re-imbursement system. One obvious reason is that I do believe market driven initiatives are often actually more successful if you want rapid and continuous improvement, but also for the simple reason that regulatory changes on trhe EU-level is a very slow process. Read more via this link, and get even more details if you follow the links in that blog post.

Some concluding remarks...

Some concluding remarks...


E-postadressen publiceras inte. Obligatoriska fält är märkta *